Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02288234 · ClinicalTrials.gov registry record
Telavancin Observational Use Registry (TOUR)
A clinical trial, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- 1,063
- Enrollment target
NCT02288234 is a clinical trial that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 1,063 participants.
The verdict
NCT02288234 has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- 1,063 participants
- Enrollment target
Study Summary
The telavancin observational use registry (TOUR) will collect data to support study of the efficacy, safety, and pattern of use of telavancin in hospital-based inpatients and in outpatients being treated in infusion centers who are receiving clinician directed telavancin therapy.
Interventions
- DRUG Vibativ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,063 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02288234
The ClinicalTrials.gov registry entry for NCT02288234 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,063 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vibativ is the first listed.
NCT02288234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02288234 about?
NCT02288234 is a clinical study titled "Telavancin Observational Use Registry (TOUR)". The telavancin observational use registry (TOUR) will collect data to support study of the efficacy, safety, and pattern of use of telavancin in hospital-based inpatients and in outpatients being treated in infusion centers who are receiving clinician directed telavancin therapy.
What is the current status of trial NCT02288234?
This trial is currently completed. The enrollment target is 1,063 participants. The study started on 2014-11. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02288234?
The interventions under investigation include: Vibativ (DRUG).
Who is sponsoring clinical trial NCT02288234?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.